CD274 and neoplasm: Prior studies have demonstrated that biomarkers such as PD-L1 immunohistochemical expression, tumor mutation burden (TMB), tumor infiltrating lymphocytes (TILs), and instability/defective mismatch repair (MSI/dMMR) have the potential to predict the efficacy of immunotherapy.